All In Biotech

Drug Trial Radar · NCT04192500

Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

A Phase 2a, Single Center, Randomized, Double-blind, Controlled Study to Evaluate the Immunogenicity and the Safety of One Dose of OVX836 Influenza Vaccine at Two Dose Levels (90 µg and 180 μg), in Comparison to Influvac TetraTM, Quadrivalent Seasonal Influenza Sub-unit Vaccine, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Last checked: Nov 19, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Dec 11, 2019

Primary completion

Sep 7, 2020

Study completion Sep 7, 2020

Sponsor

Lead sponsor
OsivaxIndustry
Sponsor type
Industry
Collaborators
University Ghent
First posted
Dec 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 2a clinical study is designed to evaluate the immunogenicity and the safety of one dose of OVX836 influenza vaccine administered IM, confirm the dose level and regimen, and expand immunogenicity and safety data to adults through age 65.

Conditions

  • Influenza

Interventions

  • OVX836Biological

    One single administration intramuscularly at Day 1.

  • Quadrivalent seasonal influenza vaccine (Influvac TetraTM)Biological

    One single administration intramuscularly at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NP-specific IFNγ T-cell increase measured by ELISPOT at Day 8 versus pre-injection baseline (Day 1) in the pooled age strataTime frame: at Day 8 versus pre-injection baseline (Day 1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Vaccinology (CEVAC)

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.